Bone Graft Substitute Market Size was valued at USD 2.83 Billion in 2022. The Bone Graft Substitute industry is projected to grow from USD 3.02 Billion in 2023 to USD 5.41 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.70% during the forecast period (2023 - 2032).
Bone grafting is a medical procedure used to repair severe bone fractures. Bone grafts are implantable materials that are used in the surgical process to help with bone healing, bone formation, and osseous reconstruction. A bone substitute is a synthetic, artificial, or biologically organic fusion that can be used instead of autogenous or allogenous bone to treat a bone defect.
October 2023: No events or activities scheduled.Orthofix Medical Inc., a prominent multinational company specializing in spine and orthopedic products, has officially received 510k approval and is now fully launching OsteoCove™, an innovative synthetic graft with bioactive properties. OsteoCove is a product that comes in both putty and strip forms. It was specifically designed to have excellent bone-forming powers and easy handling for various spine and orthopedic procedures. Orthofix is a dominant force in the demineralized bone matrices (DBM) and cellular allograft sectors.
The introduction of OsteoCove greatly enhances their range of biologics and supports their commitment to providing top-quality solutions in all main bone grafting categories. OsteoCove is composed of a mixture of β-tricalcium phosphate (ß-TCP) and hydroxyapatite (HA), along with type-I bovine collagen. It has a unique surface structure that is specifically designed to stimulate the formation of bone. This has been demonstrated by its ability to promote bone growth in a difficult muscle pouch model. The unique surface chemistry and microporosity of this product have been proven to enhance bone growth more effectively than other advanced synthetic grafts now on the market.
June 2023: BONESUPPORT™, a rising leader in orthobiologics for bone injury therapy, has announced the release of the next version of their revolutionary antibiotic-releasing bone graft alternative, CERAMENT G. Enhancements have been implemented on CERAMENT G to enhance user-friendliness and minimize ecological footprint. All components in the kit of the latest edition of CERAMENT G are now surface sterile, while maintaining the same composition, mechanism of action, and clinical results as prior versions. Furthermore, the product's durability has been prolonged by an additional year, resulting in a total shelf life of three years.
The enhancements result in a more streamlined surgical process, resulting in improved user experience and higher operational efficiency. In addition, the new CERAMENT G kit has been reduced in size by 28% in terms of its physical dimensions, and the amount of packing material used has been decreased by 35%. The enhancements to the kit were implemented following thorough discussions with consumers.
March 2022: Molecular Matrix, Inc. (MMI), a leader in regenerative medicine polymer technology, is proud to announce the full launch of its Osteo-P® Synthetic Bone Graft Substitute (BGS) for use in the musculoskeletal system. Osteo-P® BGS is made using MMI’s hyper-crosslinked carbohydrate polymer (HCCP) technology platform which has been engineered to optimize the microenvironment for bone repair and regeneration.
Osteo-P® BGS’s natural matrix does not require the addition of a collagen xenograft or other binder to improve handling.
In March 2022, Biocomposites of Keele, UK, reached a multi-year agreement with Zimmer Biomet to exclusively distribute Genex Bone Graft Substitute in the United States with a new mixing system and new delivery options. In order to facilitate the preparation process by shortening it and elongating working time, U.S genex has been upgraded, and a closed-mixing system has been introduced. Additionally, this bone graft substitute can now be delivered using more options, such as injections, moldings, or beads, depending on the surgeon’s preference, according to a news release from Biocomposites.
In November 2022, Lithoz announced its development of the LithaBone HA 480 for 3D-printed bone replacements. It is understood that the material is a bioresorbable ceramic bone graft substitute; however, they have developed those materials following what they call ‘intensive collaboration’ with users of previous Lithoz bone graft substitute products. But then again, this material is said to have gone through some substantial improvements concerning mechanical properties such as higher wall thicknesses, among others like possible geometries lattice structure size and processability. For example, while wall thicknesses ranging from 1.6mm up to 10mm are allowed by Lithoz’ LithaBone HA 480 compared with prior replacement materials of bones produced by Lithoz include “strongly reduced overpolymerisation with an improved depth of cure resulting in a more stable manufacturing process.”
In June 2020, Bioventus launched SIGNAFUSE Bioactive Bone Graft in strip format since it was first made available as a putty in 2014. This was said by Signafuse manufacturer Bioventus, who also stated that their strips offer outstanding intraoperative handling characteristics due to rapid hydration. Among them are longer ones, which measure anything from twenty-five millimetres up to two hundred meters. Besides being lengthy, these larger strips will provide an excellent choice for broad, multi-level operations.
COVID-19 Impact Analysis
Although COVID-19 will have a short-term effect on market growth, the market will largely be unaffected by the pandemic because orthopedic procedures, including bone graft substitute devices, are in high demand due to the subsequent rise in the demand for bone-related treatments. Additionally, many nations have begun easing lockdowns and other COVID-19-related precautions, allowing for the resumed performance of orthopedic procedures.
The situation following the COVID-19 outbreak has improved tremendously since governments worldwide have started to relax norms, giving way to business activities operating once again. Movement restrictions are no longer an issue, which is encouraging companies to now expand their presence in other regions, other than their own.
For instance, in October 2022, CGBio, a South Korean healthcare provider, has procured a firm hold on the sale of its advanced synthetic bone graft material that has clinical uses in spine, orthopedic, trauma and dental applications across North America via a license-out and product supply contract with a U.S. medical device company, Orthofix.
CGBio's material called Novosis, has been approved in South Korea, Mexico, India, and Southeast Asia, and can be described as a recombinant human bone morphogenetic protein-2 bone growth material that is used as a scaffold for the development of a new bone while offering moldable handling.
The growth of biocompatible synthetic bone grafts, an increase in demand for dental bone graft processes, and an increase in road injury and joint disorder incidences are some of the key factors driving market expansion. Bone graft substitutes market growth is being hindered by factors like high surgical costs, risks associated with bone graft procedures, and complications.
THERAVET has developed a new line of calcium-phosphate and biological bone substitutes, BIOCERA-VET. BIOCERA-VET® is a full range of innovative, easy-to-use, efficient & cost-effective bone substitutes indicated in bone surgeries where a bone graft is required and as a palliative alternative in the management of canine osteosarcoma.
The frequency of traffic accidents is increasing. For instance, the WHO estimates that every year, 1.35 million people die in road accidents and 20 to 50 million people suffer non-fatal injuries. Additionally, the National Trauma Institute estimates that the economic toll of trauma cases in 2014 increased to USD 671 billion, including lost productivity and healthcare costs. There are many ways to treat diseases and injuries with bone grafting. If a fracture has multiple, complex, or poor healing after initial treatment, it may be used. In a diseased joint, it is also used for fusion, which aids in the healing of two bones. Fusion is typically carried out on the spine.
The price of a bone graft varies greatly depending on the circumstance and the patient's health. For instance, a single implant region will cost anywhere between USD 300 and USD 800 for simple bone grafting for dental purposes using synthetic bone. Hospitalization is required and adds to the cost of a bone graft operation when a patient's bone material is obtained from various body locations.
A crucial component of health policy and planning is accurate and comparable estimates of each nation's health spending. They are essential to advancing regional, global, and national health objectives. The WHO published a new report on global health spending on February 20, 2019, which showed that high-income countries saw an increase in health spending of 4% and low- and middle-income countries saw an increase of 6% globally. Less than 40% of primary health care spending is covered by the government. Due to the significant market opportunity for bone graft substitutes, many businesses are entering the space.
Based on the Product Type, the global Bone Graft Substitute market has been divided into Allograft, {Machine allografts, Demineralized Bone Matrix (DBM)}, Bone Graft Substitute {Synthetic Bone Grafts, Bone Morphogenic Proteins}, Cell-based Matrices. The spinal fusion segment holds the largest share of bone graft substitute market. Allografts come from people other than the recipient of the graft. It is typically sourced from a bone bank and is mainly taken from cadavers who have donated their bone so that it can be used for people who are alive and in need.
Based on the Application, the global Bone Graft Substitute market is divided into Spinal Fusion, Joint Reconstruction, Long Bone, Dental, Foot & Ankle. The spinal fusion segment will grow the fastest. It's crucial to realize that bone grafts do not perform the spinal fusion or heal the distress in the spine. However, a bone graft creates a setting in which a strong bridge can develop. The spine is supported by a bone graft, which also enables the body to regenerate the bone and fuse the affected section of the spine.
February 2022
Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced the full market launch of Opus™ BA, a synthetic bioactive bone graft solution for cervical and lumbar spine fusion procedures.
Opus BA can be used to fill bone voids or gaps in the skeletal system that are not intrinsic to the stability of bony structure. Opus BA acts as a scaffold allowing bone growth across the surface that is reabsorbed and replaced with natural bone during the healing process.
Regional Analysis
By region, the global market has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. Europe accounted for the largest market share. Asia-Pacific is projected to exhibit the highest CAGR during the review period.
October 2022
LifeNet Health is showcasing the most advanced allograft biologics for fusion during the North American Spine Society (NASS) 2022 Annual Meeting in Chicago Oct. 12-14 (Booth #3216). The global leader in allograft solutions and processing technology will feature the growing body of evidence supporting LifeNet Health's solutions for thoracic, cervical, and lumbar fusions — including ViviGen® Cellular Bone Matrix, PliaFX® Prime moldable demineralized fibers, and VertiGraft® structural allografts.
Europe Market
Europe held a large share of the global bone graft substitute market. With increased awareness of bone graft substitutes and rising healthcare costs, Europe has emerged as a significant market. The region has significant growth potential, which will aid in the global market's expansion in the coming years. Countries such as the UK and Germany are expected to make major contributions to the growth of the regional market, which will benefit the industry.
Asia-Pacific Market
The bone graft substitute market is predicted to grow fastest in Asia-Pacific. Due to the presence of developing economies such as India, China, and South Korea as well as the growing potential patient population, the region offers lucrative opportunities for players in the bone graft substitute market. Additionally, it is anticipated that the market will expand during the review period due to the growing geriatric population and rising healthcare spending. The bone graft market is expanding quickly in the Asia-Pacific region owing to research and development initiatives.
Competitive Landscape
The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reach across the globe with diverse product portfolios. Companies such as Johnson & Johnson Services Inc, Geistlich Pharma, AlloSource, Smith & Nephew, and Integra Lifesciences Holdings Corporation dominate the global Bone Graft Substitute market due to product differentiation, financial stability, strategic developments, and diversified regional presence. The players are focused on investing in research and development. Furthermore, they adopt strategic growth initiatives, such as expansion, product launches, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.
Prominent players in the global Bone Graft Substitute market include
Objectives of the Study
The objectives of the study are summarized in 5 stages. They are as mentioned below:
Market Size and Forecast:
To identify and estimate the market size for the global Bone Graft Substitute market segmented by Hardware, Types, and Applications, by value (in US dollars). Also, to understand the consumption/ demand created by consumers of Bone Graft Substitute during the period of 2020-2030
Market Landscape and Trends:
To identify and infer, the drivers, restraints, opportunities, and challenges for the global Bone Graft Substitute market
Market Influencing Factors:
To find out the factors which are affecting the sales of Bone Graft Substitute among consumers
Impact of COVID-19:
To identify and understand the various factors involved in the global Bone Graft Substitute market affected by the pandemic
Company Profiling:
To provide a detailed insight into the major companies operating in the market. The profiling will include the financial health of the company past 2-3 years with segmental and regional revenue breakup, product offering, recent developments, SWOT analysis, and key strategies.
Intended Audience
| Report Attribute/Metric | Details |
| Market Size | 2032: USD 5.41 billion |
| CAGR | 6.70% CAGR (2023-2032) |
| Base Year | 2022 |
| Forecast Period | 2023-2032 |
| Historical Data | 2021 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Application |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Medtronic, AlloSource, Zimmer Biomet Holdings Inc, Stryker, Smith & Nephew, Johnson & Johnson Services Inc, Baxter International Inc, Integra Lifesciences Holdings Corporation, Orthofix Holdings Inc, Geistlich Pharma, SeaSpine |
| Key Market Opportunities | The orthopedic care sector has received a lot of investment |
| Key Market Drivers | Rising incidence of road injuries and joint disorders |
Bone Graft Substitutes Market Highlights:
Frequently Asked Questions (FAQ) :
The study period of the global Bone Graft Substitute market is 2023 - 2032
The global Bone Graft Substitute market is growing at a CAGR of 6.70% over the next 10 years
Asia Pacific is expected to register the highest CAGR during 2023 - 2032
Europe holds the largest share in 2021
Johnson & Johnson Services Inc, Geistlich Pharma, AlloSource, Smith & Nephew, and Integra Lifesciences Holdings Corporation are the major companies operating in the global Bone Graft Substitute market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
